Zistdaru danesh

Zistdaru Danesh is a prominent Iranian biotechnology company dedicated to the development and production of high-tech pharmaceutical products, with a specialized focus on Multiple Sclerosis (MS) therapies. Established in 2005 and based in the Pardis Technology Park, the company has successfully commercialized several critical biosimilars and complex generics, including Ziferon (interferon beta-1b) and Tebif (teriflunomide). Zistdaru Danesh maintains state-of-the-art manufacturing facilities that adhere to international Good Manufacturing Practice (GMP) standards, enabling the supply of affordable, high-quality medicine to patients in Iran and the broader region. The company's research and development efforts are centered on expanding its portfolio into oncology and other immunological disorders. Through its commitment to innovation and self-sufficiency in biotechnology, Zistdaru Danesh has become a key player in the Middle Eastern life sciences sector.